Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06091865 · ClinicalTrials.gov registry record · Phase 3
A Study to Compare How Well Odronextamab Combined With Chemotherapy Works and How Safe it is Against Rituximab Combined With Chemotherapy, in Adult Patients With Previously Untreated Diffuse Large B-cell Lymphoma
A Phase 3 study of Diffuse Large B Cell Lymphoma (DLBCL), sponsored by Regeneron Pharmaceuticals.
- Active
- Registry status
- Phase 3
- Development phase
- 904
- Enrollment target
- 20
- Study locations
NCT06091865: Active Phase 3 study of Diffuse Large B Cell Lymphoma (DLBCL), sponsored by Regeneron Pharmaceuticals.
NCT06091865 is a Phase 3 study of Diffuse Large B Cell Lymphoma (DLBCL) that is active but no longer recruiting, run by Regeneron Pharmaceuticals. The registered enrollment target is 904 participants, above the 172-participant average among 10 other Diffuse Large B Cell Lymphoma (DLBCL) trials with a reported enrollment target (426% higher). The trial reports 20 study locations across 13 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06091865, a Phase 3 study of Diffuse Large B Cell Lymphoma (DLBCL), is active but no longer recruiting, sponsored by Regeneron Pharmaceuticals.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 904 participants
- Enrollment target
- 20
- Study locations
Study Summary
This study is researching an experimental drug called odronextamab, referred to as study drug, when used in combination with chemotherapy. The study is focused on patients with Diffuse Large B-cell Lymphoma (DLBCL) that have not been treated before (called "previously untreated"). Patients with DLBCL that have come back after treatment (called "relapsed"), or have not responded to treatment (called "refractory"), can also participate in this study. This study will be made up of Part 1A, Part 1B, and Part 2.The aim of Part 1A and Part 1B of the study is to see how safe and tolerable the study drug in combination with chemotherapy is and to determine the dose and schedule of the study drug to be combined with chemotherapy in Part 2 of the study. The aim of Part 2 of the study is to see how effective the combination of the study drug with chemotherapy is in comparison with the combination of rituximab (the comparator drug), and chemotherapy, the current standard of care treatment approved for DLBCL. Standard of care means the usual medication expected and used when receiving treatment for a condition. The study is looking at several other research questions, including: * What side effects may happen from taking the study drug when combined with chemotherapy * How much study drug is in the blood at different times * Whether the body makes antibodies against the study drug (which could make the study drug less effective or could lead to side effects) * The impact from the study drug on quality of life and ability to complete routine daily activities
Primary Outcome
Part 1A
Conditions Studied
Interventions
- DRUG Cyclophosphamide
- DRUG Doxorubicin
- DRUG Rituximab
- DRUG Vincristine
- DRUG Odronextamab
Study Locations (20)
California
- David Geffen School of Medicine at UCLA - Los Angeles
- University of California Irvine Medical Center - Orange
- University of California (UC) Davis - Sacramento
Indiana
- Indiana University Melvin and Bren Simon Comprehensive Cancer Center - Indianapolis
- St Vincent Ascension at Peyton Manning Childrens Hospital - Indianapolis
- Investigative Clinical Research of Indiana - Noblesville
Michigan
- Henry Ford Health System - Detroit
- Cancer and Hematology Centers of Western Michigan - Grand Rapids
New York
- Stony Brook University Hospital - Stony Brook
- Clinical Research Alliance Inc - Westbury
New South Wales
- Liverpool Hospital - Liverpool
- Calvary Mater Newcastle - Waratah
Kentucky
- University of Kentucky - Lexington
Massachusetts
- Beth Israel Deaconess Medical Center - Boston
New Jersey
- Rutgers Cancer Institute of New Jersey - New Brunswick
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 904 participants |
| Start Date | 2023-12-13 |
| Est. Completion | 2029-09-02 |
| Phase | Phase 3 |
What the registry record for NCT06091865 still lists
NCT06091865 is an interventional study that assigns participants to a tested intervention. The registered 904 participants enrollment target is mid-sized for trials with a published cap, above the 172-participant average among 10 other Diffuse Large B Cell Lymphoma (DLBCL) trials with a reported enrollment target (426% higher).
The record links to 1 condition, with Diffuse Large B Cell Lymphoma (DLBCL) appearing as the primary indexed condition, and to 5 interventions - of which Cyclophosphamide is the first listed.
NCT06091865 names 20 study sites across 13 states, led by California, Indiana, Michigan.
Frequently Asked Questions
What is clinical trial NCT06091865 about?
NCT06091865 is a clinical study titled "A Study to Compare How Well Odronextamab Combined With Chemotherapy Works and How Safe it is Against Rituximab Combined With Chemotherapy, in Adult Patients With Previously Untreated Diffuse Large B-cell Lymphoma". This study is researching an experimental drug called odronextamab, referred to as study drug, when used in combination with chemotherapy. The study is focused on patients with Diffuse Large B-cell Lymphoma (DLBCL) that have not been treated before (called "previously untreated"). Patients with DLBC...
What is the current status of trial NCT06091865?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 904 participants. The study started on 2023-12-13. Estimated completion is 2029-09-02.
What conditions does trial NCT06091865 study?
This clinical trial studies the following conditions: Diffuse Large B Cell Lymphoma (DLBCL).
What interventions are being tested in trial NCT06091865?
The interventions under investigation include: Cyclophosphamide (DRUG), Doxorubicin (DRUG), Rituximab (DRUG), Vincristine (DRUG), Odronextamab (DRUG).
Who is sponsoring clinical trial NCT06091865?
This trial is sponsored by Regeneron Pharmaceuticals, which has 280 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06091865 being conducted?
This trial has 20 study locations across California, Indiana, Kentucky, Massachusetts, Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Diffuse Large B Cell Lymphoma (DLBCL)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06091865's enrollment target sits among peer trials
904 1st of 10 higher than 10 of 10 other Diffuse Large B Cell Lymphoma (DLBCL) trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Diffuse Large B Cell Lymphoma (DLBCL) trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy
RECRUITING · Phase 3
-
A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies
RECRUITING · Phase 1
-
A Study of Glofitamab-based Treatment in People With Diffuse Large B-cell Lymphoma
RECRUITING · Phase 2
-
A Study of NX-2127 in Adults With Relapsed/Refractory B-cell Malignancies
RECRUITING · Phase 1
-
A Study to Evaluate the Impact of Mosunetuzumab Consolidation for Older Patients With Diffuse Large B-cell Lymphoma (DLBCL) Who Have Detectable Amounts of ctDNA (Circulating Tumor DNA) at the End of Treatment With Pola-R-mini-CHP
RECRUITING · Phase 2
-
Comprehensive Geriatric Assessment to Predict Toxic Events in Older Patients With Non-Hodgkin Lymphoma With Imbedded Pilot Study of Pre-Phase Therapy
ACTIVE NOT RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05769777 · 901 participants · Phase 2
Open Label, Long-term Study Evaluating Safety and Efficacy of Subcutaneous Amlitelimab in Participants Aged 12 Years and Older With Moderate to Severe Atopic Dermatitis
- NCT05658497 · 908 participants
Pregnancy Exposure Registry for Vumerity (Diroximel Fumarate)
- NCT02352116 · 900 participants · NA
Evaluation of Post-PACU Pain Management in Pediatric Surgery
- NCT02414347 · 900 participants
F 18 T807 Tau PET Imaging of Alzheimer's Disease
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI